Multiple steroid hormone levels in depressed patients and normal controls before and after exogenous ACTH by Gehris, Timothy L. et al.
Psycho~uroendocrinology, Vol. 16, No. 6, pp. 481-497, 1991 0306-4530/91 $3.00+0.00 
Printed in Great Britain ©1992 Pergamon Press ple 
MULTIPLE STEROID HORMONE LEVELS 
IN DEPRESSED PATIENTS AND NORMAL CONTROLS 
BEFORE AND AFTER EXOGENOUS ACTH 
TIMOTHY L. GEHRIS, I ROGER KATHOL, 1'2 WILLIAM H.  MELLER, 3 
JUAN F. LOPEZ, 4 a n d  RICHARD S. JAECKLE 5 
Departments of 1psychiatry and 2Internal Medicine, University of Iowa, College of Medicine, Iowa City, Iowa, 
3Department of Psychiatry, University of Minnesota Hospitals and Clinics, Minneapolis, Minnesota, and 
4Mental Health Research Institute; University of Michigan, Ann Arbor, Michigan, U.S.A.; 5posthumous 
(Received 27 August 1990; in final form 1 February 1991) 
SUMMARY 
Forty depressed patients and 36 age- and sex-matched controls were given 250 ~tg ACTHl_24 by 
IV bolus. Plasma steroid hormone levels were measured prior to and 60 rain after ACTH adminis- 
tration. The depressed patients had significantly greater cortisol (F), 1 l-deoxycortisol (S), 
androstenedione (AD), and 17c~-hydroxyprogesterone (17ct-OHP)responses (delta; p<0.05) and a 
marginally greater l 113-hydroxyandrostenedione (1113-OHAD) response (delta; p = 0.091) than the 
controls. There was no significant difference in the corticosterone (B) response between the two 
groups. 
With the exception of 11 ~-OHAD, all the steroid hormones were significantly negatively corre- 
lated with age in the controls, but only S and AD marginally demonstrated this relationship in the 
depressed patients. F, S, AD, 17et-OHP, and B, but not ll~-OHAD, were significantly positively 
correlated with each other in the controls, but only F was significantly correlated with AD in the 
depressed patients. These data suggest that the hypercortisolemia found in some depressed patients 
involves increased precursor and metabolite levels both at baseline and in response to exogenous 
ACTH, compared to controls. Furthermore, variability in these precursors is greater in depressed 
patients, and their relationship to age is lost. These findings are consistent with the hypothesis that 
adrenal products other than cortisol also could be related to affective symptoms. 
INTRODUCTION 
REVIEW OF THE LITERATURE reveals a substantial amount  of  evidence of  hypercort isol ism in 
some populations o f  depressed patients (Stokes, 1987; Arana & Mossman, 1988). While much 
of  the research on hypercor t i solemia  in depressed patients has centered on the l imbic and 
hypothalamic systems, few studies have investigated adrenal gland activity, despite the fact that 
reversal of  corticosteroid production by adrenal resection or ablation in patients with Cushing 's  
disease is an effective means of  treating the high incidence o f  depression in this population 
(Kathol, 1985); i.e., there appears to be something in adrenal output that effects emotion. 
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The adrenocorticotropin (ACTH) stimulation test has been used to investigate peripheral 
abnormalities of the hypothalamo-pituitary-adrenal axis by assessing adrenal cortex responsive- 
ness. Some investigators have reported a higher cortisol response to exogenous ACTH in 
actively depressed patients compared to normal controls (Amsterdam et  al. ,  1983; 1986; 
Jaeckle et al., 1987) or to those who have recovered from their depression (Endo et  al., 1974; 
Amsterdam et  al., 1987a; Fang et  al., 1988a). Others (Carpenter & Bunney, 1971; Sclare & 
Grant, 1972) have not observed this difference. 
When using the ACTH stimulation test to study adrenal responsiveness in depressive 
illness, most investigators have concentrated only on the adrenal steroid, cortisol. The secre- 
tion of the cortisol precursors progesterone (Strott et  al. ,  1969), 17tx-hydroxyprogesterone 
(Strott et  al. ,  1969), and ll-deoxycortisol (Liddle et  al. ,  1962), as well as corticosterone 
(Peterson & Pierce, 1960) its precursor, deoxycorticosterone (Crane & Harris, 1966; Harris et  
al. ,  1967; Biglieri et  al . ,  1969; ), and some adrenal androgens, dehydroepiandrosterone 
(Vaitukaitis et  al., 1969), androstenedione (Rivarola et al., 1966) and 1 ll3-hydroxyandrostene- 
dione (Lejeune-Lenain et  al. ,  1980), also are stimulated by ACTH in man. These steroid 
hormones, however, have received little or no attention in assessments of adrenal responsive- 
ness to endogenous or exogenous ACTH in depressed patients. 
Since biologic activity is largely determined by the chemical structure and stereotaxis of 
steroid molecules, precursors and metabolites of cortisol could play a significant role in produc- 
ing changes in CNS activity, i.e., in influencing the development of affective symptoms. It is 
known, for instance, that cortisol can adversely affect neuronal function (Sapolsky, 1985) and 
that the receptors which mediate glucocorticoid effects are sensitive to the structure of the 
compound (McEwen et  al., 1986). Studies on rats have identified two distinct classes of corti- 
costeroid receptors in the brain which resemble corticosteroid receptors found in the kidney 
(type I) and the liver (type II) (reviewed in McEwen et al., 1986; 1988; De Kloet et  al., 1987; 
De Kloet & Reul, 1987). The type I receptor is primarily localized in the hippocampus and has 
a high affinity for aldosterone and the major glucocorticoids (corticosterone in the rat and 
cortisol in other species) (McEwen et  al., 1986; 1988; De Kloet et  al., 1987; De Kloet & Reul, 
1987). The type II receptor has a lower affinity for glucocorticoids and does not bind mineralo- 
corticoid steroids (McEwen et  al., 1986; 1988; De Kloet et al., 1987; De Kloet & Reul, 1987). 
This receptor is more widely distributed, occurring not only in the hippocampus but also in the 
lateral septum, central amygdala, supraoptic nucleus, paraventricular nucleus, and nucleus 
tractus solitarii (McEwen et al., 1986; 1988; De Kloet et  al., 1987; De Kloet & Reul, 1987). 
Because the type II receptors have lower glucocorticoid affinity it is thought that these receptors 
are only occupied during the corticosteroid stress response, while the type I receptors are 
occupied during the basal state (McEwen et al., 1986; 1988; De Kloet et  al., 1987; De Kloet & 
Reul, 1987). In turn, because of the widespread distribution of the type II receptors, the regula- 
tion of the CNS response to stress is, at least in part, likely affected by high levels of corticos- 
teroids. It is possible that steroid compounds other than cortisol, even when produced in much 
smaller amounts, could be more closely related to the production of depressive symptoms than 
would be cortisol. 
In this study we investigated the basal hormonal state and the responses of cortisol, l l -  
deoxycortisol, corticosterone, 17ct-hydroxyprogesterone, androstenedione, and ll~i-hydroxyan- 
drostenedione to exogenous ACTHl_24 administration in patients with major depression and in 
normal controls. 
CORTICOSTEROID LEVELS IN DEPRESSED PATIENTS 483 
SUBJECTS AND METHODS 
Subjects 
Sixty-four patients were recruited from the inpatient psychiatric service at the University of Iowa Hospitals 
and Clinics (UIHC). The patients were screened by a research assistant with the National Institute of Mental 
Health's Diagnostic Interview Schedule (DIS) (Robins et al., 1981) (n = 39) or by clinical interview by a psy- 
chiatrist (n = 25), and all diagnoses were confirmed by consensus among the investigators. Of the 64 patients 
recruited, 50 met DSM-III (American Psychiatric Association, 1980) criteria for major depressive disorder 
(MDD). Ten of these 50 patients were excluded for the following reasons: one patient also met criteria for 
anti-social personality disorder, three were receiving carbmazepine, three were taking oral contraceptives, one 
was using hydrocortisone cream, one was receiving estrogen replacement, and one had recently received ECT. 
Therefore, 40 patients with MDD (13 male and 27 female) were studied before and after the administration of 
exogenous ACTHI_24. The mean age (+SD) was 35.0+14.3 yr (range 16-70 yr) (men: 32.9+14.1 yr, women: 
36.0+14.6 yr). Only one patient was not receiving a psychotropic medication. The medications and doses 
were unchanged from admission and throughout the testing, to avoid the effects of drug withdrawal (Devanand 
et al., 1984; Dilsaver & Greden, 1984; Krause et al., 1987). The 17-item Hamilton Rating Scale for 
Depression (HRSD) (Hamilton, 1960) and the Carroll Rating Scale for Depression (CRSD) (Carroll et al., 
1981) were administered to 36 patients. All patients gave informed written consent prior to entering the study. 
Thirty-six age- and sex-matched healthy control subjects were identified by advertisement or contacted from 
a list of research participants obtained from the Clinical Research Center at the UIHC. There were 15 men and 
21 women; their average age was 35.8 + 12.6 yr (range 21-62 yr) (men: 32.9 + 11.9 yr; women: 38.0 + 12.9 yr). 
All were free of psychiatric symptoms, were on no medications at the time of the study, and gave informed 
written consent. Twenty-eight completed an HRSD, and 32 completed a CRSD. All 36 control subjects were 
studied before and after administration of ACTH 1_24. 
Procedures 
Each participant received 250 lag ACTH1_24 by IV bolus between 1300h and 1700h to take advantage of the 
relatively steady basal afternoon state. An IV butterfly catheter was routinely placed 30 min before testing 
began. Blood samples for steroid analysis were drawn before and 60 rain after the administration of ACTHl_24 
into chilled tubes containing EDTA. All specimens were centrifuged and the plasma removed and frozen at 
-20 ° C within 1 hr of collection. Some of the subjects (35 patients and 30 controls) also completed a dexameth- 
asone suppression test (DST) by taking orally 1 mg of dexamethasone at 2330h. The DST was performed at 
least 48 hr after the ACTH test. Blood samples for post-DST cortisol levels were drawn at 0800h and 1600h 
the following day. DST nonsuppressors were identified as those with post-DST cortisol levels > 5 lag/dl at 
either 0800h or 1600h. 
Hormone Assays 
Cortisol (F) was measured in duplicate unextracted plasma samples by a standard 125I double-antibody 
radioimmunoassay (RIA) developed at the Medical Research Facility at the UIHC as described previously 
(Jaeckle et al., 1987). Intra-assay coefficients of variation were 8.3%, 6.6% and 5.1%, and interassay co- 
efficients of variation were 14.6%, 13.4% and 16.7%, for cortisol levels of 2.7 lag/dl, 11.7 lxg/dl and 23.6 lag/dl, 
respectively. 
ll-deoxycortisol (S), 17¢t-hydroxyprogesterone (170t-OHP), androstenedione (AD), and corticosterone (B) 
were measured by RIA kits purchased from ICN Biomedicals, Los Angeles, CA (formerly Radioassay Systems 
Laboratories, Carson, CA). 1 ll3-hydroxyandrostenedione (1 ll3-OHAD) was measured by RIA kits purchased 
from Inter Sci Diagnostics, Los Angeles, CA. 
S and 17ct-OHP levels were measured in duplicate unextraeted plasma samples. Both assays used 125I- 
labelled steroids as the ligand and goat anti-rabbit "t-globulin to separate the bound from the unbound steroid. 
The S intra-assay coefficients of variation were 7.4% and 3.3%, and the interassay coefficients of variation 
were 4.1% and 14.1%, for levels of 0.21 Ixg/dl and 2.41 lag/d, respectively. Cross-reactivity with 17¢t-OHP 
was 3.9%, deoxycorticosterone 0.22%, progesterone 0.16%, and cortisol 0.09%. All other cross-reactivities 
were <0.03%. 17o~-OHP intra-assay coefficients of variation were 0.0%, 4.9% and 3.3%, and interassay 
coefficients of variation were 18.2%, 11.2% and 8.9%, for levels of 0.11 ng/ml, 0.73 ng/ml and 3.99 ng/ml, 
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respectively. The 17ct-OHP antiserum cross-reacted 0.58% with 17tz-hydroxypregnenolone, 0.18% with pro- 
gesterone, 0.06% with deoxycorticosterone, and 1.48% with 11-deoxycortisol. All other related steroid cross- 
reactivities were < 0.02%. 
Samples for AD levels were extracted with ethyl acetate:hexane (3:2), as per the manufacturer's procedure, 
prior to RIA. The radioligand was 125I-labelled AD, and the bound and unbound steroid was separated by goat 
anti-rabbit y'globulin. The intra-assay coefficients of variation were 8.1%, 8.3% and 7.5%, and the interassay 
coefficients of variation were 12.6%, 7.4% and 9.7%, for levels of 0.69 ng/ml, 2.20 ng/ml and 6.14 ng/ml, re- 
spectively. The AD antiserum cross-reacted 1.79% with estrone, 0.64% with testosterone, 0.07% with proges- 
terone, 4.40% with DHEA-S, and 3.50% with DHEA. All other related steroid cross-reactivities were <0.02%. 
The 1 ll3°OHAD RIA also required prior extraction with ethyl acetate:hexane (1:1). The radioligand was 
3H-labelled 11~-OHAD, and the bound and unbound steroid were separated with saturated ammonium sulfate. 
The intra-assay coefficients of variation were 6.1% and 6.3%, and the interassay coefficients of variation were 
7.2% and 8.2%, for levels of 115 and 393 ng/dl respectively (few l l~-OHAD assays were run; therefore, this 
information is from Inter Sci Diagnostics). The antiserum is very specific for llI~-OHAD, with little cross- 
reactivity with androstenedione (2.64%) and adrenosterone (0.12%). All other related steroids cross-reacted 
<0.01%. 
B determinations required sample extraction and purification prior to the RIA. To 2 ml plasma (pipetted into 
40 ml glass centrifuge tubes) was added approximately 500 cpm of 3H-corticosterone, 200 ng d-aldosterone- 
21-acetate (internal standard), and 2 ml double-distilled H20. Following a 30-min incubation period at room 
temperature, the samples were extracted with 10 ml methylene chloride, gently shaken, and centrifuged at 
1500 rpm for 20 min. The organic phase was removed and placed in separate clean glass centrifuge tubes. 
This was repeated two more times, combining all the organic phase for each sample (approximately 30 ml). 
The extract then was washed four times with 5 ml 0.1 N NaOH, with removal and discard of the NaOH after 
each wash. After the final wash, the extract was drawn into a glass syringe, filtered through a 0.22 Ixm durapore 
filtering system (Millipore, Bedford, MA), and blown down to dryness under nitrogen in a 37 ° C water bath. 
The sides of the glass tubes then were rinsed with 0.5 ml of ethanol, vortexed, the ethanol transferred to a 1 ml 
glass test tube, and the tube tightly sealed with parafilm and frozen at -20 ° C until the purification step. 
Purification was done by high-pressure liquid chromatography (HPLC). The HPLC system consisted of a 
Shimadzu Model LC-4A liquid chromatograph (Shimadzu, Columbia, MD); DuPont UV spectrophotometer 
detector (DuPont, Wilmington, DE); DuPont Model 860 column compartment; Shimadzu C-R1A Chromatopac 
integrator; and Pharmacia Model FRAC-100 fraction collector (Pharmacia, Piscataway, NJ). Once the HPLC 
system was equilibrated, the samples were evaporated to less than 50 ~tl, drawn up into a Hamilton syringe, and 
shot into the HPLC system with a Rheodyne injector. The sample was applied to a 50 mm C-18 guard column 
(Jones Chromatography, Columbus, OH) and then a 15 cm, 5 kt Apex ODS column (Jones Chromatography) at 
45°C with a flow rate of 2 ml/min, resulting in a pressure of about 140 kg/cm 2. The detector was set at 
254 nm with an absorbance range of  0.01 A. The eluent  system was methanol :ace toni t r i l e :water  
(MeOH:ACN:H20). The water was double-distilled and deionized, and the methanol and acetonitrile were 
HPLC grade. All reagents were filtered through a 0.5 I~m filter and degassed with helium for about 20 min 
prior to use. The eluent gradient began at 38:1:61 (MeOH:ACN:H20) and went to 55.5:1:43.5 by 20.5 min, 
and then the column was washed with 38:55:7 eluent for 5 min and equilibrated again at 38:1:61 for 20 min. 
The retention time for B under these conditions was about 14 rain. The B fraction was collected in 
16× 125 mm glass tubes via the FRAC-100, and the tubes sealed and frozen at -20°C until all samples were 
purified. 
The samples then were lyophylized in a Labconco Model 75040 Freeze Dryer 8 (Labconco, Kansas City, 
MO), reconstituted with 2.5 ml assay buffer, and incubated at room temperature for a minimum of 30 min prior 
to RIA. From each reconstituted sample a recovery % was determined and used in calculating the final sample 
concentration. The average sample recovery (+ SD) was 50.9% + 14.1%. The radioligand was 3H-corticos- 
terone, and the bound steroid was separated from the unbound by charcoal-dextran.  The intra-assay 
coefficients of variation were 20.7%, 9.2% and 7.2%, and the interassay coefficients of variation were 6.9%, 
8.7% and 8.6%, for corticosterone levels of 2.89 ng/ml, 6.57 ng/ml and 29.7 ng/ml, respectively. The anti- 
serum cross-reacted 100% with cortisol, 4.5% with progesterone, 1.7% with 17(x-hydroxyprogesterone, 2.5% 
with 20ct-dihydroprogesterone, 4.5% with deoxycorticosterone, 3.0% with 11-deoxycortisol, 3.0% with aldos- 
terone, 1.3% with androstenedione, 3.1% with testosterone, and 1.1% with dihydrotestosterone. All other 
related steroid cross-reactivities were < 0.01%. 
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Statistical Methods 
Data are reported as mean:i:SD. Steroid hormone responses to exogenous ACTH within each group were 
analyzed with paired t-tests. Comparisons between the MDD and control groups were done with the Student's 
unpaired t-test. When variances between groups were grossly unequal, approximation for the degrees of 
freedom was determined according to Sattenhwaite's formula (Satterthwaite, 1946). For comparisons of three 
groups (i.e., comparisons made based on DST status), one-way analysis of variance (ANOVA) was used, and 
when appropriate a Tukey's post hoc test was used to identify between-group differences. Pearson's correlation 
coefficient was used to estimate the fit between two parameters. Analysis results were considered statistically 
significant when the confidence level was <0.05. 
RESULTS 
The symptom rating scale scores and compar isons  for  the M D D  patients and controls  and 
for subgroups of  the M D D  patients are presented in Table I. Ten o f  the 35 patients (29%) com- 
pleting the DST were DST nonsuppressors  (DST-NS) and 25 were suppressors  (DST-S). Two 
of  the 30 controls  (7%) were DST-NS. 
Al l  steroid hormones  demonst ra ted  a marked increase ( p <  0.0006)  fo l lowing the Iv  bolus 
250 l.tg ACTHl_24 in both the M D D  patients and the controls.  The t ime of  day the A C T H  stim- 
ulation test was per formed had no significant affect on the basal  levels or  the responses of  the 
measured steroid hormones.  Table II  shows the mean steroid levels  at basel ine,  60 rain after 
ACTH infusion, and the response (delta) to A C T H  infusion for  the controls  and patients with 
MDD. The M D D  patients  had significantly higher  basel ine F (t = 2.96; d f =  74; p = 0.004) and S 
( t=  2.63; d f =  59.8; p = 0.011) than the controls and showed a trend towards  h igher  A D  basel ine 
leve ls  ( t - -1 .70 ;  d f =  69; p = 0 .095) .  S ix ty  minu tes  fo l l owing  the A C T H  in fus ion  the M D D  
[cont'/nued on Page 488) 
TABLE I. MEAN + SD HAMILTON RATING SCALE FOR DEPRESSION (HRSD) 
AND CARROLL RATING SCALE FOR DEPRESSION (CRSD) SCORES AND COMPARISONS 
FOR THE CONTROLS AND PATIENTS WITH MDD AND SUBGROUPS OF PATIENTS WITH MDD 
Group Total N HRSD CRSD 
Controls 36 2.4 + 1.3 a (28) 2.2 + 2.7 b (32) 
MDD 40 17.6 + 6.5 (36) 27.0 + 10.9 (36) 
DST-NS 10 16.8+4.7 (8) 26.0+13.6 (9) 
DST-S 25 16.9 + 7.3 (23) 26.7+ 10.5 (22) 
Bipolar 7 22.4 + 8.1 c (7) 32.3 + 8.4 (7) 
Unipolar 33 16.4+5.6 (29) 25.8+11.2 (29) 
Psychotic 17 19.6 + 17.2 (16) 30.2 + 10 (15) 
Nonpsychotic 23 15.9+5.5 (20) 25.8+11.3 (21) 
Melancholic 15 20.3 + 7.1 (14) 32.0 + 8.6 d (14) 
Nonmelancholic 8 15.3 + 3.3 (7) 19.7+ 12.4 (7) 
Undetermined 17 
Number of observations for each measure is in parentheses. 
acontrols vs. MDD: t=12.7; df=38.4; p=0.0001 
bcontrols vs. MDD: t=13.2; df=39.7; p=0.0001 
c bipolar vs. unipolar: t= 2.36; df= 34; p= 0.024 
d melancholic vs. nonmelancholic: t= 2.66; dr= 19; p=0.016 
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TABLE II. MEAN+ SD STEROID LEVELS AT BASELINE (0) AND 60 MIN 
POST-250 [,I.G A C T H  (60) AND THE CHANGE IN LEVELS (dt), 
IN THE CONTROLS AND PATIENTS WITH M D D  
Controls M D D  p 
S (35) (39) 
[ ~ g / d l ]  0 .24+ .12 3 4 +  .22 0.011 
60 .49 _+ .15 .68_+ .31 0.001 
A .25_+ .13 .33_+ .21 0.04 
F (36) (40) 
[p.g/dl] 0 10.5_+4.1 13.6_+5.0 0.004 
60 24.5+ 6.0 33.7-+ 12.6 0.0001 
A 13.9+5.0  20.1+11.7  0.004 
AD (34) (37) 
[ng / ml] 0 1.45 -+ .67 1.75 + .82 0.095 
60 2.48 -+ 1.06 3.27 + 1.28 0.006 
A 1.02 + .69 1.51 + .92 0.014 
17cc-OHP (32) (24) 
[ng / ml] 0 .93 + .63 1.10 _+ .62 0.315 
60 2.29 + 1.08 3.65 + 1.94 0.021 
A 1.66 + .92 2.55 + 1.84 0.036 
B (28) (25) 
[ng / ml] 0 4.33 + 4.38 5.20 + 3.89 0.452 
60 31.8 -+ 15.1 32.3 -+ 8.96 0.89 
A 27 .5+I5 .1  27.1+8.11 0.908 
l l ~ - O H A D  (9) (17) 
[ n g / d l ]  0 159.7 _+ 59.8 170.8 _+ 85.5 0.733 
60 253.0 _+ 83.0 317.9 _+ 120.0 0.161 
A 87.4 _+ 47.9 147.2 _+ 95.1 0.091 
The number  measured for each group is in parentheses under  the respective columns. 
TABLE III. MEAN-F SD STEROID RESPONSE (DELTA) TO 250 ~G A C T H  
IN CONTROLS WHO WERE DEXAMETHASONE SUPPRESSORS (CONTROLS) AND PATIENTS 
WITH M D D  WHO ARE SUPPRESSORS (DST-S) AND NONSUPPRESSORS (DST-NS) 
Controls 
M D D  
D S ~ S  D S ~ N S  
S [ m g / d l ]  .26 + .14  (28) .31 _+ .20 (25) .35 + .27 (9) 
F[p .g /d l ]*  14.8+4.9 a (28) 17.5+6.1 a (25) 26 .4+20.5  b (10) 
AD [ n g / m l ]  1.12+.71 (28) 1.36+ .97 (24) 1 . 8 3 + / 8 0  (9) 
17~-OHP [ n g / m l ]  1 .72+.98 (26) 2.51+ 1.93 (17) 2 .94+ 2.40 (7) 
B [ n g / m l ]  27.3_+15.9 (25) 25.0_+6.9 (15) 34 .1+7 .6  (6) 
11~-OHAD [ n g / d l ]  87.2_+51.2 (8) 145.8+ 108.5 (10) 166.8+89.8 (5) 
Difference among groups with different letters: *p< 0.001 (Tukey's p< 0.05). 
The number  measured for each group is in parentheses. 
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TABLE IV. MEAN+ SD STEROID RESPONSE (DELTA) TO 250 I.I.G A C T H  IN THE PATIENTS WITH M D D  
GROUPED BY MEDICATION AND THE MOST COMMON DRUG COMBINATION TREATMENTS 
WITH FIVE OR MORE OBSERVATIONS 
Medication S F AD 17ot-OHP B 11~-OHAD 
[~tg/dl] [~tg/dl] [ng/ml]  [ng/ml]  [ng/ml]  [ng/dl]  
TCA 
Off .29+ .18 (10) 
On .35 ± .22 (29) 
LI 
Off .33± .21 (25) 
On  .35 + .22 (14) 
BNZ 
Off .33 + .23 (26) 
On .34± .18 (13) 
AP 
Off .35 ± .23 (27) 
On .31 ± .17 (12) 
TCA + LI .37± .24 (9) 
TCA + BNZ .34±.19 (8) 
TCA + AP .27+ .18 (7) 
LI + BNZ .33± .18 (7) 
LI + AP .38+ .15 (6) 
26.1+19.9(11) 1.72+.94(10) 2.55+1.90(7) 
17.8± 5.5 (29) 1.44± .92 (27) 2.54± 1.87 (17) 
20.7±12.5 (25) 1.47±.81 (24) 2.72± 1.90 (17) 
19.1 ± 10.7 (15) 1.60± 1.13 (13) 2.16+ 1.73 (7) 
22.1+ 13.4 (26) 1.43+.86 (24) 2.90±2.14 (15) 
16.4±6.7(14) 1.68±1.05(13) 1.98±1.05(9) 
19.9± 13.5 (28) 1.36+ .86 (26) 2.83+ 2.09 (16) 
20.5+6.5(12) 1.88+1.01 (11) 2.01±1.12(8) 
16.0±5.7(9) 1.48±1.15(8) (n<5) 
15.8+ 5.2 (8) 1.53± .89 (8) 1.81 ± .60 (5) 
18.7+7.4 (7) 1.84+.99 (6) (n<5) 
18.9+4.9 (7) 1.88+ 1.19 (6) (n<5) 
15.2± 8.0 (7) 1.87± 1.19 (6) (n< 5) 
25.3±8.9 (6) 162.8±95.8 (7) 
27.7+8.0 (19) 136.2±98.1 (10) 
25.8±7.9 (17) 123.4+79.9 (10) 
29.9±8.4 (8) 181.1 + 110.7 (7) 
28.6+7.5 (14) 143.8+102.8 (10) 
25.2±8.8(11) 15Z1±90.6(7) 
28.3+9.1 (16) 138.5+87.4 (11) 
24.9+5.7 (9) 163.0+ 114.9 (6) 
34.9 ± 4.0 (5) (n< 5) 
25.8+8.0 (7) (n<5) 
26.2+5.2 (5) (n<5) 
(n< 5) (n< 5) 
(n< 5) (n< 5) 
Abbreviations: TCA=tricyclic antidepressants; LI =lithium; BNZ=benzodiazepines; AP= antipsychotics. 
Number of observations in parentheses. 
TABLE V. PEARSONrS CORRELATION OF AGE WITH MEASURED STEROIDS AT BASELINE 
n r p 
C o n S o l s  
S 35 -.586 0.0002 
F 36 -.410 0.013 
AD 34 -.650 0.0001 
17~-OHP 32 -.554 0.001 
B 28 -.522 0.004 
11~-OHAD 9 +.309 0.419 
M D D  
S 39 -.385 0.016 
F 40 -.123 0.450 
AD 37 -.409 0.012 
17~-OHP 24 -.369 0.076 
B 25 -.205 0.326 
11b-OHAD 17 -.055 0.834 
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TABLE VI. CORRELATION OF STEROID LEVELS WITH EACH OTHER/ 
P VALUE FOR CORRELATION COEFFICIENT AT BASELINE 
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(32) (28) (9) 
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(32) (28) (9) 
.695/.0001 .435/.021 .258/.502 





.084/.697 .228/.272 -.285/.268 
(24) (25) (17) 
-.047/.826 .368/.070 .073/.781 
(24) (25) (17) 
.161/.453 .311/.130 .350/.168 





Number of observations is in parentheses. 
patients had significantly higher F (t = 4.15; d f=  57.0; p = 0.0001), S (t = 3.41; d f=  56.2; 
p = 0.001), AD (t= 2.84; df= 69; p = 0.006), and 17c~-OHP (t= 2.43; df= 33.7; p = 0.021) levels 
than the controls. The MDD patients had a significantly greater response (delta) to exogenous 
ACTH for F ( t=3.02;  df=53.8;  p=0 .004) ,  S ( t=2.10;  df=63.3 ;  p=0 .040 ) ,  AD (t=2.53;  
df=69;  p=0.014) ,  and 17(x-OHP (t=2.19; df=31.6;  p=0 .036)  than the controls and had a 
trend toward a greater 11 [~-OHAD response (t = 1.76; df= 24; p = 0.091) (Table II & Fig. 1). 
When the MDD patients were subcategorized by DST suppression status and compared to 
only the controls who suppressed normally following dexamethasone, the patients with MDD 
who were DST-NS had the greatest F response (F=5.65; df= 2,60; p=0.0057).  In general, the 
MDD DST-NS patients had the greatest response for all the steroids, followed by the MDD 
DST-S and the controls  except  for  B where the MDD DST-S had the lowest  response 
(Table III). MDD patients with psychosis had a significantly greater 111$-OHAD response 
(n = 6 :233 .8  + 57.9 ng/dl) than those with nonpsychotic MDD (n = 11 : 99.9 + 76.4 ng/dl) 
(t= 3.72; df= 15; p =0.002). No other significant differences based on the presence of psy- 
chosis were noted. No significant hormone differences were observed between patients with 
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unipolar and bipolar MDD or in those with melancholic versus those without melancholic 
depression. 
The most common treatment medication in the MDD patients was tricyclic antidepressants 
(29). Other treatment drugs were lithium (15), benzodiazepines (14), antipsychotics (12), and 
monoamine oxidase inhibitors (4), or a combination of psychotropic medications. The effect 
that these medications may have on the steroid hormone response to exogenous ACTH is pre- 
sented in Table IV. 
All compounds measured, with the exception of 11~-OHAD, decreased with age in the 
control subjects; only S and AD demonstrated a similar, but not nearly as robust, relationship in 
the MDD patients (Table V). Except for l l~-OHAD, all of the steroid hormones were 
significantly positively correlated with each other at baseline in the controls (Table VI). lll3- 
OHAD also demonstrated a positive correlation with the other steroids but was measured in 
fewer subjects and did not reach significance. This relationship is reflected in the MDD 
patients only between AD and F. Sixty minutes following the infusion of ACTHIt only S 
and AD (r=.438; p=0.01) ,  S and 17a-OHP (r=.484; p=0.005)  and AD and 17ct-OHP 
(r=.397; p = 0.027) remained significantly correlated in the controls. None of the compounds 
were significantly correlated with each other in the MDD patients 60 min after ACTHl_24. 
Only the response of S to exogenous ACTH was significantly correlated with the duration 
of illness in the MDD patients (r=-.392; p=0.014). Likewise, the severity of symptoms was 
significantly positively correlated only with the response of 1113-OHAD to ACTH (HRSD" 
r =.550; p = 0.034; CRSD: r =.482; p = 0.059). 
DISCUSSION 
The ACTH stimulation test has been used previously in assessing adrenocortical respon- 
siveness in depressed patients (Holsboer et al., 1984), in depressed patients retested following 
treatment or recovery from their illness (Sclare & Grant, 1972; Endo et al., 1974; Gerken & 
Holsboer, 1986; Amsterdam et  al., 1987a), and in normal controls compared to depressed 
patients (Carpenter & Bunney, 1971; Amsterdam et al., 1983; 1986; Jaeckle et al., 1987; Fang 
et al., 1988a). With the exception of a few studies, however, investigators have limited their 
studies to the cortisol (F) response. In the few studies that have measured steroid hormones 
other than F (Holsboer et al.,  1984; Gerken & Holsboer, 1986), normal controls were not 
included. In this study we measured F, ll-deoxycortisol (S), corticosterone (B), 17a-hydrox- 
yprogesterone (17a-OHP), androstenedione (AD), and 11[~-hydroxyandrostenedione (1113- 
OHAD) to further address adrenal responsiveness following acute ACTH stimulation and to 
investigate its effect on the biosynthesis of adrenal steroids in depressed patients. Where these 
hormones occur in the production and metabolism of corticosteroids is summarized in Fig. 2. 
We report augmented responses of F, S, AD, 17~-OHP, and ll~-OHAD, but not of B, to 
acute stimulation with a supraphysiological dose of ACTH in a group of patients with MDD 
compared to normal controls. Since some of the subjects in this study were also included in a 
study by Jaeckle et  al. (1987) and the methods were the same, the F response is similar to that 
which Jaeckle et al. reported. The increased F response in the depressed patients is also in 
agreement with the findings of Amsterdam et  al. (1983) who also used a dose of 250 ~tg ACTH 
but administered it in the moming. However, others have not observed this difference (Car- 
penter & Bunney, 1971; Fang et al., 1988a). This difference is most likely due to differences in 
the methods used. Carpenter and Bunney (1971) infused the ACTH continuously over a 4-hr 
morning period rather than giving an Iv bolus. Fang et al. (1988a) first suppressed endogenous 
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ACTH with dexamethasone and then stimulated with a much smaller dose (< 4 p.g), also in the 
morning. 
The studies of Amsterdam et al. (1983; 1986; 1987a) and Jaeckle et al. (1987) suggested 
that the differences found in the F response may be due to an increased adrenal sensitivity to 
ACTH in depressed patients. Fang et al. (1988a; 1988b) responded that when using a supra- 
physiological dose (250 p.g ACTH), adrenal secretory capacity is more likely being measured 
rather than adrenal sensitivity. It is possible, therefore, that the increased steroid response in the 
depressed patients is due to adrenal hypertrophy, since chronic stimulation with ACTH is 
known to increase adrenal size. Thus stimulation with a supraphysiological dose of exogenous 
ACTH to enlarged adrenal glands theoretically would result in greater steroid production. In 
fact, computed tomography scans of adrenal glands in depressed patients have shown increased 
adrenal volume in 50% of the patients studied (Amsterdam et  al., 1987b). Increased adrenal 
weight also has been reported in suicide victims compared to persons with no known history of 
psychiatric illnesses dying from traumatic injuries or sudden medical complications (Domvini- 
Zis & Zis, 1987). Because in the present study we also used a supraphysiological dose of 
ACTH, we cannot conclude that the differences seen between the MDD patients and controls 
were due to an increase in adrenal responsiveness vs. hypertrophy of the adrenal glands. Only 
further investigation of steroid responsiveness to more physiological doses of exogenous 
ACTH, and/or endogenous ACTH stimulated via other provocative tests such as the corti- 
cotropin-releasing hormone stimulation test or insulin-induced hypoglycemia, can clarify this 
point. 
B was the only steroid measured that did not show an augmented response compared to the 
controls. It is possible that, since the measurement of 13 was the most difficult because it 
required such extensive sample preparation prior to analysis, differences could be explained on 
the basis of laboratory error. However, one would have expected the error to have been equal 
in both the controls and the patients with MDD. Furthermore, while controls were not included 
in the studies of Holsboer et al. (1984) and Gerken and Holsboer (1986), our 13 levels are in 
agreement with the levels they reported. An alternative explanation is that the production of B 
becomes maximally stimulated (approximately 32 ng/ml) with a supraphysiological dose of 
ACTH. In depressed patients this favors 17~-hydroxylation of AS-pregnenolone and proges- 
terone. Glucocorticoid and adrenal androgen production would continue to increase, but miner- 
alcorticoid production would not. 
Finally, the data in Table III suggest that the augmented hormone responses may be associ- 
ated with DST status. Previous studies have reported significant correlations of the response of 
F to 250 ~tg ACTH with post-DST 1600h F levels (Holsboer et aL, 1984; Jaeckle et al., 1987). 
Therefore, had DST-NS patients, i.e., those with the highest production of corticosteroids, been 
better represented in our study, it is likely that the differences in hormone response between the 
MDD patients and controls would be more robust, including the response of B. In fact, a 
greater B response to exogenous ACTH has previously been reported in DST-NS depressed 
patients, but only when retested following recovery from illness (Gerken & Holsboer, 1986). 
Another way that our data could be interpreted is that depressed patients have adrenal 
hyper-responsiveness by way of enhanced activity or increased synthesis of enzymes involved 
in the biosynthesis of corticosteroids and adrenal androgens, particularly those under the 
control of ACTH, resulting in hypercortisolemia. ACTH affects steroidogenesis at two levels. 
First, acute ACTH stimulation causes a rapid increase in steroidogenesis by increasing the rate 
of conversion of cholesterol to AS-pregnenolone, the rate-limiting step in steroidogenesis 
(Fig. 2), by increasing the amount of mitochondrial cholesterol (substrate) bound to cytochrome 
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FIG. I: Scattergram of the change in hormone levels after ACTHI_24 in controls and 
patients with MDD. (A) 1 1-Deoxycortisol, {B) Cortlsol, (C) Corticosterone, [D) Andros- 
tenedione, (E) 17a-Hydroxyprogesterone, IF) 11~-Hydroxyandrostenedione. 
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P-450 to be converted to AS-pregnenolone (Simpson & Waterman, 1983). An acute supraphys- 
iological dose of ACTH therefore would cause a marked increase in the adrenal steroids which 
was observed in both the controls and depressed patients in this study. Second, ACTH has a 
tropic affect on steroidogenesis by maintaining adequate levels of steroidogenic enzymes 
(Simpson & Waterman, 1983). Several of these steroidogenic enzymes require cytochrome P- 
450, a heme-containing enzyme found in the adrenocortical mitochondria and microsomes, as 
well as in other organs (Rapp, 1986). Synthesis of mitochondrial cytochrome P-450sc c 
(cholesterol side chain cleavage) (DuBois e t  al . ,  1981) and P-45011p (1113-hydroxylase) 
(Kramer et  al., 1983a), and microsomal cytochrome P-450c21 (21-hydroxylase) (Funkenstein 
et  al., 1983) and P-45017 a (17a-hydmxylase) (Zuber et  al., 1985) have been shown to increase 
in ACTH-treated cells. Furthermore, increased 17a-hydroxylase activity has been reported in 
in vitro studies utilizing cultured bovine adrenocortical cells treated with ACTH (McCarthy et  
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BIOSYNTHESIS OF STEROID HORMONES 
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FIG. 2: Biosynthesis  of steroid hormones .  Major pa thways  are indicated by the solid arrow- 
heads, minor  pathways are indicated by the open arrowheads, and multiple reactions are indi- 
cated by two consecu t ive  a r rows .  Abbrevia t ions :  S C C = s i d e  c h a i n  cleavage; 17a=  17ct- 
hydroxylase; 3~HSD = 5-ene-31~-hydroxysteroid dehydrogenase  and 3-oxosteroid isomerase;  
C 17,20 = 17,20 |yase; C21 = 21-hydroxylase;  11 ~ = 1 l~-hydroxylase;  17~HSD = 1713-hydroxy- 
steroid dehydrogenase; 11~HSD = I ll3-hydroxysteroid dehydrogenase. 
treated rabbits (Fevold et al., 1978). ACTH apparently does not have this same effect on 21- 
hydroxylase (Funkenstein et al., 1983) or ll~-hydroxylase (Kathol et  al., 1987). However, 
Kramer et al. (1983b) reported that secretion of 17~-hydroxysteroids and C19 steroids (i.e., 
androgens) was enhanced further by the action of ACTH to increase 17a-hydroxylase activity 
and possibly 17,20 lyase. The possibility of 17,20 lyase activity being enhanced by ACTH in 
conjunction with 17(~-hydroxylase is very likely since 17,20 lyase and 17(x-hydroxylase are 
now thought to be localized on the same polypeptide chain (Nakajin & Hall, 1981) and associ- 
ated with one protein (Nakajin et al., 1981). The action of 17(~-hydroxylase lies at an important 
juncture in the biosynthetic pathway of adrenal steroids. Without it, glucocorticoids and 
adrenal androgens would be nonexistent. Likewise, 17,20 lyase is necessary for further conver- 
sion of 17(~-OHP and 17(x-hydroxypregnenolone to the androgens. Therefore, any enhance- 
ment of 17a-hydroxylase and 17,20 lyase activities or increased production of cytochrome 
P-450Cl 7 (17(~-hydroxylase/17,20 lyase) could potentially favor increased production and 
secretion of the 17(z-hydroxysteroids and adrenal androgens. 
Elevated levels of ACTH in dexamethasone-resistant depressed patients have been reported 
by several investigators (Fang et al., 1981; Reus et al., 1982; 1983; Kalin et al., 1982). Pfohl 
et al. (1985a; 1985b) reported an increase in ACTH levels in depressed patients over a 24-hr 
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period, with significant increases at varying times compared to controls. It is possible, then, 
that in depressed patients chronically higher circulating levels of ACTH are maintaining 
increased amounts of steroidogenic enzymes by stimulating synthesis of cytochrome P-450 and 
enhancing the enzyme activity of 17~-hydroxylase and 17,20 lyase. Therefore, when acute 
ACTH stimulation occurs in depressed patients, greater amounts of enzymes are available for 
the necessary conversions in the steroidogenic pathways, causing an increased production and 
secretion of the steroids. Furthermore, if 17t~-hydroxylase and 17,20 lyase activities are 
enhanced due to the chronically elevated ACTH while 5-ene-313-hydroxysteroid dehydrogenase 
and 3-oxosteroid isomerase are not, then the steroids converted from 17¢t-OHP (i.e., F, S, AD, 
etc.) would demonstrate a greater response, while the mineralcorticoid pathway (i.e., B) would 
respond less robustly. Enhanced 17¢t-hydroxylase and 17,20 lyase activities are consistent with 
the differences we found in the baseline data. Levels of F, S, and AD were elevated in the 
depressed patients compared to the controls. 
Another explanation of our data could be a question of stimulated thresholds. It is possible 
that each adrenal steroid has a different responsive threshold to ACTH and that depressed 
patients have higher thresholds than controls. However, since we only tested a single, supra- 
physiological dose of ACTH, this explanation cannot not be adequately addressed here. 
Our data also suggest that there is a change in the way depressed patients respond to ACTH 
in other ways besides preferential production of 17¢t-hydroxysteroids and adrenal androgens. 
There also was loss of the relationship among the basal levels of the steroids measured. This 
lost relationship could be ascribed simply to the increased variance in the depressed individu- 
als; however, this in itself is a difference between controls and patients with depression, and 
found in numerous endocrine evaluations in the literature, which needs an explanation. Both 
controls and depressed patients in this study had their testing performed in the same structured 
environment. Is there something about their life circumstances, depressive treatment, or emo- 
tional state which has led to a less-coordinated production of adrenal hormones? 
Perhaps a more important finding in our study was the consistent negative correlation be- 
tween age and basal hormone levels in the controls. This negative relationship was largely lost 
in the patients with depression. These findings support what has been previously reported re- 
garding age and other measures of corticosteroid production. Normal controls had no change, 
or a reduction, of glucocorticoid excretion with increasing age (Hamburger, 1954; Juselius & 
Kenny, 1974; Kathol et  al. ,  1989). Findings on post-dexamethasone F levels also suggest 
either no effect of age or a decrease with age (Tourigny-Rivard et  al., 1981; Lewis et  al., 1984), 
although other studies question whether this is the case (Oxenkrug et  al., 1983). Patients with 
depression, on the other hand, have consistently been found to have an increase in urinary gluco- 
corticoid excretion or DST nonsuppression with advancing age (Jacobs et  al., 1984; Sharma et  
al., 1988; Kathol et  al., 1989). Many studies also have reported significantly positive correla- 
tions of age with post-dexamethasone F levels in depressed patients (Asnis et  al., 1981; Lewis 
et al., 1984; Nelson et  al., 1984; Holsboer et  al., 1986; Whiteford et al. ,  1987; Maes et  al., 
1990) as well as with baseline F levels (Asnis et  al., 1981; Whiteford et  al., 1987). Still others 
have reported a significant positive correlation of age with the F response to human cortico- 
tropin-releasing hormone stimulation in depressed patients but not in controls (von Bardeleben 
& Holsboer, 1989). The fact that our patients with depression lost the negative relationship of 
the hormones with age is in the predicted direction for this group, even though a positive corre- 
lation was not found. This suggests that there is a consistent difference between those with 
depression who, if anything, increase corticosteroid production with age, and those without a 
history of depression, who generally show a decrease in corticosteroid production with age. 
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Our study is not without its problems. All but one of our patients were on one or more psy- 
chotropic drugs, and we cannot role out the possibility that these drugs contributed to the differ- 
ences observed. However, DST-NS depressed patients who are treated with antidepressants 
have been reported to suppress normally following treatment (Holsboer et  al., 1982; Greden et  
al., 1983). This suggests that if these drugs were affecting the adrenal response, then it is most 
likely that their effect would have been to diminish the differences by lowering the F, and very 
likely the other steroid, levels towards those seen in the controls. Since these studies only 
measured F, however, the possibility of these drugs affecting the other steroid concentrations 
remains unanswered. Only further research into the effects these drags have on adrenal respon- 
siveness can clarify this point. Another contributing factor is that our female subjects were not 
controlled for their menstrual cycle. This may constitute a problem when interpreting the 17ct- 
OHP data, because of the low levels before ovulation and the rise in progesterone and 17tx- 
OHP levels from the corpus luteum following ovulation. However, when the male patients and 
controls were compared, the differences remained. In any case, this should probably be taken 
into account when measurements of 17ct-OHP are done. 
In conclusion, we report increased adrenal steroid responses for S, AD, 17tx-OHP, and 11~- 
OHAD, but not B, similar to those previously reported for F (Jaeckle et  al., 1987) in depressed 
patients compared to controls following acute ACTH stimulation. Any of these could be more 
closely related to the development of depression or characteristic symptoms of depression than 
F. Interestingly, androgens also have been independently related to depressive symptoms in 
those taking synthetic androgens (Pope & Katz, 1987; 1988; Perry et  al., 1989). Our prelimi- 
nary findings with 11 [B-OHAD suggest that it may have a relationship to psychosis in depres- 
sion. Increased production of 17(x-hydroxysteroids and adrenal androgens may be due to an 
enhanced 17ct-hydroxylase and 17,20 lyase, activity or increased synthesis of cytochrome P- 
450c17, following chronic higher levels of ACTH in depressed patients. Alternatively, the aug- 
mented responses could be related to a defect in the negative feedback mechanism of 
corticosteroids on pituitary and hypothalamic function, since the DST-NS depressed patients 
consistently had the greatest steroid responses to exogenous ACTH. However, the possibility 
that psychotropic drugs influenced the augmented responses cannot be ruled out, since all but 
one of the patients with MDD were on one or more psychotropic drugs. 
During the basal state the depressed patients showed a loss of uniform relationships among 
the adrenal steroids and a loss of the age-related decrease in steroid levels that occurred in the 
controls. The lost negative correlation of age with basal steroid levels may suggest a genetic 
predisposition to increased corticosteroid production, which is age-related. While evidence is 
plentiful suggesting that hypercortisolemia in depression may be caused by abnormalities in the 
limbic and hypothalamic neuroregulatory systems, abnormalities in peripheral systems also 
may be involved. This study presents data that warrants further investigation of the role of 
cortisol precursors and metabolites in depressive illness. 
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